Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin

  • Authors:
    • Angela M. Wong
    • Yanjung Zhang
    • Kelly Kesler
    • Max Deng
    • Lucas Burhenn
    • David Wang
    • Aune Moro
    • Zhaoping Li
    • David Heber
  • View Affiliations

  • Published online on: September 1, 2010     https://doi.org/10.3892/etm.2010.145
  • Pages: 1013-1017
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Rabdosia rubescens is a herbal root extract of traditional Chinese medicine (TCM) used to treat inflammatory diseases and oral cancers. A key principle of TCM is that multiple ingredients in a plant extract are more effective and less toxic than a single purified active ingredient or a purified drug derived from a plant product. Rabdosia rubescens extract (RRE) contains terpenoids and flavonoids, but the most active ingredient within the extract attributed to the inhibition of cancer is the kaurene diterpene, oridonin. In order to research synergy with a complete plant extract, the effects of RRE on the inhibition of prostate cancer cell proliferation were compared to the effects of pure oridonin alone in vitro. Three groups of 8 SCID mice bearing human prostate cancer xenografts (LAPC-4) were administered either RRE containing 0.02 mg/g oridonin, pure oridonin at a dose of 0.02 mg/g, or pure oridonin at a dose of 0.1 mg/g, by gavage for 5 days/week for 4 weeks. RRE and pure oridonin at 0.1 mg/g inhibited tumor growth to a similar extent, while oridonin at a dose of 0.02 mg/g did not. Therefore, in comparison to RRE, five times more pure oridonin was required to obtain equivalent prostate xenograft growth inhibition. Since the nuclear factor-κB signaling pathway and inflammation are implicated in prostate carcinogenesis, gene microarray analysis was conducted and demonstrated activation of genes by RRE that was not evident with oridonin treatment alone. This study demonstrated that genomic methods and xenograft studies are capable of demonstrating the benefits of the synergy of whole plant extracts rather than active ingredients isolated and purified as drugs.
View Figures
View References

Related Articles

Journal Cover

November-December 2010
Volume 1 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wong AM, Zhang Y, Kesler K, Deng M, Burhenn L, Wang D, Moro A, Li Z and Heber D: Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin. Exp Ther Med 1: 1013-1017, 2010.
APA
Wong, A.M., Zhang, Y., Kesler, K., Deng, M., Burhenn, L., Wang, D. ... Heber, D. (2010). Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin. Experimental and Therapeutic Medicine, 1, 1013-1017. https://doi.org/10.3892/etm.2010.145
MLA
Wong, A. M., Zhang, Y., Kesler, K., Deng, M., Burhenn, L., Wang, D., Moro, A., Li, Z., Heber, D."Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin". Experimental and Therapeutic Medicine 1.6 (2010): 1013-1017.
Chicago
Wong, A. M., Zhang, Y., Kesler, K., Deng, M., Burhenn, L., Wang, D., Moro, A., Li, Z., Heber, D."Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin". Experimental and Therapeutic Medicine 1, no. 6 (2010): 1013-1017. https://doi.org/10.3892/etm.2010.145